Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
113.54
-5.97 (-5.00%)
At close: Sep 12, 2025, 4:00 PM EDT
115.00
+1.46 (1.29%)
After-hours: Sep 12, 2025, 7:59 PM EDT
Repligen Revenue
Repligen had revenue of $182.37M in the quarter ending June 30, 2025, with 14.81% growth. This brings the company's revenue in the last twelve months to $673.96M, up 8.73% year-over-year. In the year 2024, Repligen had annual revenue of $634.44M with 0.33% growth.
Revenue (ttm)
$673.96M
Revenue Growth
+8.73%
P/S Ratio
9.45
Revenue / Employee
$379,053
Employees
1,778
Market Cap
6.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 634.44M | 2.08M | 0.33% |
Dec 31, 2023 | 632.36M | -169.17M | -21.11% |
Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RGEN News
- 9 days ago - Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 16 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 22 days ago - Repligen Corporation to Present at Upcoming September Conferences - GlobeNewsWire
- 4 weeks ago - Repligen Corporation: Still Navigating Through The Covid Cliff - Seeking Alpha
- 6 weeks ago - Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 - Benzinga
- 6 weeks ago - Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization - GlobeNewsWire
- 6 weeks ago - Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance - GlobeNewsWire